Home
News
Create
Screeners
Insights
Sudeep Pharma
681.
80
-6.15
(-0.89%)
Market Cap
₹7,700.84 Cr
PE Ratio
45.62
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.89%
1M
+14.13%
6M
-11.93%
1Y
-11.93%
5Y
-11.93%
View Company Insights
Latest news about Sudeep Pharma
Sudeep Pharma Limited Submits Q4FY26 Compliance Certificate Under SEBI Depositories Regulations
Apr 10, 2026
Sudeep Pharma Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) on April 10, 2026, covering the quarter ended March 31, 2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirmed no demat requests were processed as all company shares remain in electronic mode. Company Secretary Dimple Mehta submitted the documentation to NSE and BSE, ensuring continued regulatory compliance for the Gujarat-based pharmaceutical company.
Sudeep Pharma Limited Schedules Analyst and Investor Meetings for March 23, 2026
Mar 17, 2026
Sudeep Pharma Submits Q3FY26 Earnings Call Transcript Following Strong Results
Feb 12, 2026
Sudeep Pharma Makes Q3FY26 Earnings Call Audio Recording Available Online
Feb 10, 2026
Sudeep Pharma Files Regulatory Notice for VP John Garcia's Resignation
Feb 05, 2026
More news about Sudeep Pharma
22
Jan 26
Sudeep Pharma Subsidiary Acquires Gujarat Land Rights for ₹20.97 Crores Manufacturing Facility
Sudeep Pharma Limited's wholly owned subsidiary, Sudeep Advanced Materials Private Limited, has acquired leasehold rights to 80,980.19 square meters of land in Dahej, Gujarat for ₹20.97 crores. The land, purchased from DCM Shriram Fine Chemicals Limited, will be used to establish a commercial manufacturing facility for battery-grade iron phosphate. The transaction is subject to regulatory approvals and represents the company's strategic expansion into battery materials manufacturing.
16
Jan 26
Sudeep Pharma Limited Updates CIN and Company Status Following Stock Exchange Listing
Sudeep Pharma Limited has successfully updated its Corporate Identification Number (CIN) from U24231GJ1989PLC013141 to L24231GJ1989PLC013141 on the MCA website following its listing on BSE and NSE on November 28, 2025. The company's status has been changed from unlisted to listed, with the updated master data showing authorized capital of ₹15.00 crores and paid-up capital of ₹11.29 crores. The pharmaceutical company, incorporated in 1989 and based in Gujarat, maintains active compliance status under ROC Ahmedabad jurisdiction.
22
Dec 25
Sudeep Pharma Submits Q2FY26 Earnings Call Audio Recording to Stock Exchanges
Sudeep Pharma Limited has completed its Q2FY26 earnings call and submitted the audio recording to stock exchanges in compliance with SEBI regulations. The call was held on December 22, 2025, to discuss performance for the quarter and half-year ended September 30, 2025, with the recording now available on the company's website for stakeholder access.
22
Dec 25
Sudeep Pharma Q2 Results: EBITDA Drops 12.6% to ₹55.5 Cr, Margin Shrinks
Sudeep Pharma Limited reported Q2 financial results showing revenue growth of 6.7% to ₹162.80 crores, but faced significant profitability pressures with EBITDA declining 12.6% to ₹55.50 crores and EBITDA margin compressing to 34.09% from 42.66% year-on-year. Net profit also decreased 6.2% to ₹45.70 crores, indicating operational challenges despite top-line growth.
20
Dec 25
Sudeep Pharma Completes Q2FY26 Results Publication in Newspapers
Sudeep Pharma Limited completed regulatory compliance by publishing its Q2FY26 financial results extract in newspapers on December 20, 2025. The company reported consolidated revenue of ₹16,266.62 crores and net profit of ₹4,677.82 crores, with detailed results available on stock exchanges and company website.
Sudeep Pharma
681.
80
-
6.
15
(-
0.
89
%)
1 Year Returns:
-11.93%
Industry Peers
Sun Pharmaceutical
1,620.40
(-
3.
55
%)
Divis Laboratories
6,361.50
(-
0.
27
%)
Torrent Pharmaceuticals
4,117.20
(-
0.
72
%)
Dr Reddys Laboratories
1,317.10
(-
1.
04
%)
Lupin
2,296.10
(-
1.
93
%)
Cipla
1,295.00
(-
0.
83
%)
Mankind Pharma
2,267.40
(-
1.
11
%)
Zydus Life Science
927.40
(-
2.
00
%)
Aurobindo Pharma
1,413.80
(-
1.
50
%)
Glenmark Pharmaceuticals
2,299.50
(-
1.
52
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO